Cadrofloxacin Caderofloxacin; CS-940|cas:153808-85-6|西域试剂

Cadrofloxacin Caderofloxacin; CS-940,98.03%

产品编号：Bellancom-116228| CAS NO：153808-85-6| 分子式：C₁₉H₂₀F₃N₃O₄| 分子量：411.38

卡德罗沙星（Caderofloxacin；CS-940）是一种口服活性氟喹诺酮类药物，对需氧/厌氧革兰氏阳性和革兰氏阴性细菌有效。卡德罗沙星可用于传染病的研究。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-116228	￥3500.00	杭州北京（现货）
Bellancom-116228	￥5900.00	杭州北京（现货）
Bellancom-116228	￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Cadrofloxacin Caderofloxacin; CS-940

产品介绍

Cadrofloxacin (Caderofloxacin; CS-940) 是一种口服活性氟喹诺酮类活性分子，对需氧/厌氧革兰氏阳性菌和革兰氏阴性菌有效。Cadrofloxacin可用于感染性疾病的研究。

生物活性

Cadrofloxacin (Caderofloxacin; CS-940), a orally active fluoroquinolone, is effective against aerobic/anaerobic Gram-positive and Gram-negative bacteria. Cadrofloxacin can be used for the research of infectious diseases.

体外研究

Cadrofloxacin against M.tuberculosis with a MIC₅₀ of 0.25 μg/mL.
Cadrofloxacin against Acinetobacter spp. and Stenotrophomonas (Xanthomonas) maltophilia with MIC₉₀s of 0.03 and 2 μg/ml, respectively.
Cadrofloxacin against Haemophilus influenzae, Moraxella catarrhalis, and Neisseria spp. with MIC₉₀s less than or equal to 0.06 μg/mL.
Cadrofloxacin against members of the family Enterobacteriaceae with MIC₉₀s of 0.015 to 16 μg/mL (median MIC₉₀, 0.06 μg/mL).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Cadrofloxacin (9 mg/kg; i.g.; once or twice daily for 14 consecutive days) increases the activity of hepatic CYP2E1 in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats weighing 180-220 g
Dosage:	9 mg/kg
Administration:	I.g. once or twice daily for 14 consecutive days
Result:	Enhanced the expression of hepatic CYP2E1 mRNA, inducing a 1.6-fold increase compared with that of control rats. The level of CYP2E1 protein in the hepatic microsomes was significantly higher than control group, 190% of that in control rats.

体内研究

Cadrofloxacin (9 mg/kg; i.g.; once or twice daily for 14 consecutive days) increases the activity of hepatic CYP2E1 in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats weighing 180-220 g
Dosage:	9 mg/kg
Administration:	I.g. once or twice daily for 14 consecutive days
Result:	Enhanced the expression of hepatic CYP2E1 mRNA, inducing a 1.6-fold increase compared with that of control rats. The level of CYP2E1 protein in the hepatic microsomes was significantly higher than control group, 190% of that in control rats.

性状

Solid

溶解性数据

In Vitro:

DMSO : 10 mg/mL (24.31 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 80°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4308 mL	12.1542 mL	24.3084 mL
5 mM	0.4862 mL	2.4308 mL	4.8617 mL
10 mM	0.2431 mL	1.2154 mL	2.4308 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1 mg/mL (2.43 mM); Clear solution

此方案可获得 ≥ 1 mg/mL (2.43 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1 mg/mL (2.43 mM); Clear solution

此方案可获得 ≥ 1 mg/mL (2.43 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1 mg/mL (2.43 mM); Clear solution

此方案可获得 ≥ 1 mg/mL (2.43 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Biedenbach DJ, et al. Antimicrobial activity of CS-940, a new trifluorinated quinolone. Antimicrob Agents Chemother. 1995 Oct;39(10):2325-30. [Content Brief]

. Bryskier A, et al. Fluoroquinolones and tuberculosis. Expert Opin Investig Drugs. 2002 Feb;11(2):233-58. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

Cadrofloxacin Caderofloxacin; CS-940,98.03%

Cadrofloxacin Caderofloxacin; CS-940

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询